Oramed Pharmaceuticals Inc.
ORMP
$3.65
$0.010.28%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -- | -- | -- | 196.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -- | -- | -- | 196.74% |
| Cost of Revenue | -100.00% | -- | -- | -- | -- |
| Gross Profit | -100.00% | -- | -- | -- | -98.07% |
| SG&A Expenses | 21.44% | 35.05% | 11.44% | -10.37% | -17.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.70% | 33.70% | 14.91% | 21.81% | 14.95% |
| Operating Income | 0.50% | -18.05% | 0.40% | -6.26% | -5.89% |
| Income Before Tax | 637.79% | 573.14% | 678.66% | -199.25% | -339.54% |
| Income Tax Expenses | 480.14% | 255.26% | 331.37% | 22.83% | -- |
| Earnings from Continuing Operations | 488.87% | 435.11% | 897.45% | -216.74% | -376.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -17.07% | -20.93% | -39.73% | -45.54% | -81.61% |
| Net Income | 489.55% | 436.04% | 882.13% | -215.82% | -370.07% |
| EBIT | 0.50% | -18.05% | 0.40% | -6.26% | -5.89% |
| EBITDA | 0.18% | -18.90% | -0.32% | -6.96% | -6.34% |
| EPS Basic | 482.76% | 424.66% | 831.10% | -216.59% | -368.25% |
| Normalized Basic EPS | 58.66% | -52.22% | 4.28% | 12.05% | -5.34% |
| EPS Diluted | 462.46% | 405.49% | 866.41% | -223.41% | -381.12% |
| Normalized Diluted EPS | 57.79% | -52.64% | 3.48% | 11.08% | -6.25% |
| Average Basic Shares Outstanding | 0.82% | 1.34% | 1.39% | 1.14% | 1.12% |
| Average Diluted Shares Outstanding | 2.30% | 1.64% | 1.08% | 0.22% | 0.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |